Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma

Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study

(2012) Andrzej J. Jakubowiak et al.   BRITISH JOURNAL OF HAEMATOLOGY

Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: Results from a phase 2 trial

(2011) Shaji K. Kumar et al.   AMERICAN JOURNAL OF HEMATOLOGY

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

(2011) S. V. Rajkumar et al.   BLOOD

Treatment Options for Relapsed and Refractory Multiple Myeloma

(2011) Sagar Lonial et al.   CLINICAL CANCER RESEARCH

Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma

(2011) Jacob P Laubach et al.   Expert Review of Hematology

Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management

(2010) S. Vincent Rajkumar   AMERICAN JOURNAL OF HEMATOLOGY

Lenalidomide: an update on evidence from clinical trials

(2010) Meletios-Athanassios Dimopoulos et al.   BLOOD REVIEWS

Multiple myeloma – current issues and controversies

(2010) Shaji Kumar   CANCER TREATMENT REVIEWS

Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma

(2009) Paul G. Richardson et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognosis After Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Patients Treated by Breast-Conserving Therapy in Five National Surgical Adjuvant Breast and Bowel Project Protocols of Node-Negative Breast Cancer

(2009) Stewart J. Anderson et al.   JOURNAL OF CLINICAL ONCOLOGY